|
|
 Previous Article | Table of Contents | Next Article 
5-Azacytidine increases HbF production and reduces anemia in sickle cell
disease: dose-response analysis of subcutaneous and oral dosage regimens
GJ Dover, S Charache, SH Boyer, G Vogelsang and M Moyer
Varying doses of 5-azacytidine (5-aza) were given to four sickle cell
individuals for 500, 200, 100, and 30 days. The percentage of fetal
hemoglobin (HbF) containing reticulocytes (F reticulocytes) increased two-
to five-fold within five days of 5-aza therapy in all patients, with a two-
to three-fold rapid response (less than 48 hours after initial dose) in
three patients. Reticulocyte suppression was not observed prior to, during,
or after therapy in those patients who responded within 48 hours.
Subcutaneous 5-aza was given in 35-day courses consisting of every day,
every other day, or three consecutive days a week. No marrow toxicity was
observed on any of the regimens. For three patients, the highest average F
reticulocyte level was observed on the three consecutive day a week
regimen. Oral 5-aza, given with tetrahydrouridine, produced comparable F
reticulocyte response. In the two patients treated for more than 100 days,
Hb levels increased to 11 to 12 and 9 g/dL, MCV and MCH increased by 25%,
and lysate HbF levels peaked at 12% and 20%. Fetal erythroid
characteristics (i- antigen, galactokinase activity, and G gamma/A gamma
ratios) did not correlate with maximal HbF production. The frequency of
vasoocclusive crises appeared to decrease in both patients followed for
more than 100 days.
Volume 66,
Issue 3,
pp. 527-532,
09/01/1985
Copyright © 1985 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
J. Lin, J. Gilbert, M. A. Rudek, J. A. Zwiebel, S. Gore, A. Jiemjit, M. Zhao, S. D. Baker, R. F. Ambinder, J. G. Herman, et al.
A Phase I Dose-Finding Study of 5-Azacytidine in Combination with Sodium Phenylbutyrate in Patients with Refractory Solid Tumors
Clin. Cancer Res.,
October 1, 2009;
15(19):
6241 - 6249.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. S. Weinberg, X. Ji, M. Sutton, S. Perrine, Y. Galperin, Q. Li, S. A. Liebhaber, G. Stamatoyannopoulos, and G. F. Atweh
Butyrate increases the efficiency of translation of {gamma}-globin mRNA
Blood,
February 15, 2005;
105(4):
1807 - 1809.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. F. Atweh, J. DeSimone, Y. Saunthararajah, H. Fathallah, R. S. Weinberg, R. L. Nagel, M. E. Fabry, and R. J. Adams
Hemoglobinopathies
Hematology,
January 1, 2003;
2003(1):
14 - 39.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. DeSimone, M. Koshy, L. Dorn, D. Lavelle, L. Bressler, R. Molokie, and N. Talischy
Maintenance of elevated fetal hemoglobin levels by decitabine during dose interval treatment of sickle cell anemia
Blood,
May 13, 2002;
99(11):
3905 - 3908.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. D. Sher, G. D. Ginder, J. Little, S. Yang, G. J. Dover, and N. F. Olivieri
Extended Therapy with Intravenous Arginine Butyrate in Patients with {beta}-Hemoglobinopathies
N. Engl. J. Med.,
June 15, 1995;
332(24):
1606 - 1610.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. H. Lowrey and A. W. Nienhuis
Treatment with Azacitidine of Patients with End-Stage {beta}-Thalassemia
N. Engl. J. Med.,
September 16, 1993;
329(12):
845 - 848.
[Full Text]
|
|
|
|
|
